TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04212403
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group receives AMP.
Study: NCT03892434
Drug: Intravitreal bevacizumab and dexamethasone implant Injection
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
Study: NCT00120510
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
Study: NCT00120510
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
Study: NCT02640755
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hormonal Agent
Study: NCT02640755
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxane
Study: NCT02795065
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
Study: NCT02795065
Drug: Bemiparin
Normalized name: Bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
Study: NCT00451971
Drug: LEFLUNOMIDE
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00765804
Drug: Sodium citrate buffer solution with EyeGate® II System
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
Study: NCT03731091
Drug: Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily for 4 weeks (28 days)
Study: NCT03738137
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Anesthesia
Study: NCT03738137
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam is applied.
Study: NCT02295436
Drug: minodronic acid
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: comparison of different doses, ages and medication conditions
Study: NCT00427791
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV Daily Over 4 Hours for 1 Day
Study: NCT00427791
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
Study: NCT03301350
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
Study: NCT03301350
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
Study: NCT03301350
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study: NCT03301350
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study: NCT02680561
Drug: Fluticasone Propionate MDPI
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03469713
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab).
Study: NCT00669461
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone 24 mcg BID orally for 4 weeks
Study: NCT00021112
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021112
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02680561
Drug: Fluticasone Propionate/Salmeterol MDPI
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00286429
Drug: Alogliptin and insulin
Normalized name: metformin and alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
Study: NCT02680561
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00771667
Drug: Ustekinumab 1mg/kg (IP)
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
Study: NCT00771667
Drug: Ustekinumab 3 mg/kg (IP)
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
Study: NCT00771667
Drug: Ustekinumab 6 mg/kg (IP)
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
Study: NCT00771667
Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
Study: NCT00771667
Drug: Ustekinumab IV - Responder - Placebo SC (MP)
Normalized name: MP-0250
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
Study: NCT00771667
Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
Study: NCT00771667
Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP)
Normalized name: MP-0250
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
Study: NCT00771667
Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
Study: NCT00286429
Drug: Alogliptin and insulin
Normalized name: metformin and alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
Study: NCT00286429
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
Study: NCT01402271
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01402271
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01402271
Drug: pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02450513
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
Study: NCT00862693
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5ug/Biw
Study: NCT00374933
Drug: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Study: NCT00374933
Drug: Prophylactic delayed ADLI
Normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Study: NCT02620046
Drug: Vedolizumab SC
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab SC 108 mg injection
Study: NCT01024920
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: VEGF inhibitor
Study: NCT00109967
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg given IV
Study: NCT00707590
Drug: BMS-767778 or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04371926
Drug: Hydroxychloroquine Sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks
Study: NCT02012166
Drug: MK-0893 10 mg
Normalized name: vitamin MK 7
DrugBank: MK-0893 (DB12044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0893 10 mg administered orally in 240 mL of water
Study: NCT02012166
Drug: MK-0893 40 mg
Normalized name: vitamin MK 7
DrugBank: MK-0893 (DB12044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0893 40 mg administered orally in 240 mL of water
Study: NCT02012166
Drug: MK-0893 200 mg
Normalized name: vitamin MK 7
DrugBank: MK-0893 (DB12044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0893 200 mg administered orally in 240 mL of water
Study: NCT02012166
Drug: MK-0893 1000 mg
Normalized name: vitamin MK 7
DrugBank: MK-0893 (DB12044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0893 1000 mg administered orally in 240 mL of water
Study: NCT00077922
Drug: LMB-2
Normalized name: LMB-100
DrugBank: LMB-100 (DB18591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms/kg every other day (QOD) x 3 every 4 weeks
Study: NCT04917250
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/㎡，d1,4 ivdrip
Study: NCT04917250
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2500IU/㎡, maximum dose less than 3750IU
Study: NCT04917250
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/㎡，d1-3 ivdrip
Study: NCT04917250
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg/d d1-4 ivdrip
Study: NCT02804373
Drug: Oxytocin (OXT) continuous
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 24 IU of oxytocin daily during 28 days
Study: NCT00374933
Drug: Prophylactic delayed activated donor lymphocyte infusion
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Study: NCT02804373
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 24 IU of oxytocin every 3 days during 28 days.
Study: NCT00930930
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00930930
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT00930930
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00653380
Drug: Doxycycline Monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, 100 mg, single-dose
Study: NCT00653380
Drug: Monodox
Normalized name: Monodox
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, 100 mg, single-dose
Study: NCT04479202
Drug: Berberine
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
Study: NCT04479202
Drug: Montmorrillonite
Normalized name: montmorrillonite
DrugBank: Montmorillonite (DB13654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
Study: NCT02729441
Drug: ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of two renin angiotensin aldosterone inhibitors
Study: NCT02729441
Drug: perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of two renin angiotensin aldosterone inhibitors
Study: NCT00592124
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg tablet daily
Study: NCT02215044
Drug: BI 2536, intravenous
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00592124
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm/100 ml of 1% gel vaginally daily
Study: NCT00323648
Drug: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
Study: NCT02611817
Drug: Vedolizumab SC 108 mg
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab SC Injection.
Study: NCT02215044
Drug: Gemcitabine, intravenous
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01413113
Drug: pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02611817
Drug: Vedolizumab IV 300 mg
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV Injection.
Study: NCT01315899
Drug: ORM-12471 30mg
Normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as a single dose once during the crossover study as per Williams design
Study: NCT01315899
Drug: ORM-12471
Normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as a single dose once during the study as per Williams crossover design
Study: NCT03749590
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
Study: NCT00422357
Drug: Urtica Dioica (Tea bag)
Normalized name: Urtica dioica preparation
DrugBank: Urtica dioica pollen (DB10763)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01916382
Drug: Nitisinone
Normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drug
Study: NCT02942758
Drug: low-dose Azacitidine
Normalized name: ethinyl estradiol
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
Study: NCT02942758
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 45 mg p.o. continuously from day 1
Study: NCT02942758
Drug: ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
Study: NCT00584012
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00771888
Drug: lanreotide
Normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lanreotide
Study: NCT02334293
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
Study: NCT02977507
Drug: 4% Hydroquinone Topical Cream
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
Study: NCT04658849
Drug: Pioglitazone 30 Mg Oral Tablet
Normalized name: pioglitazone 30 MG Oral Tablet
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily.
Study: NCT04658849
Drug: Pioglitazone placebo tablet
Normalized name: placebo Oral Tablet
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
Study: NCT03874156
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
Study: NCT02944734
Drug: Candesartan Cilexetil 8mg
Normalized name: CANDESARTAN CILEXETIL 8MG TAB
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
Study: NCT02944734
Drug: Candesartan Cilexetil 16mg
Normalized name: CANDESARTAN CILEXETIL 16MG TAB
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
Study: NCT02944734
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5mg Daily oral administration for 8 weeks
Study: NCT02944734
Drug: Amlodipine 10mg
Normalized name: AMLODIPINE 10MG/VALSARTAN 160MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 10mg Daily oral administration for 8 weeks
Study: NCT01145456
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01153750
Drug: Glivec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00551772
Drug: SB-742457
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01923857
Drug: Androxal 25 mg
Normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01838200
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
Study: NCT01838200
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.